Belimumab in Systemic Lupus Erythematosus.
Belimumab is the only approved biological agent for the treatment of systemic lupus erythematosus (SLE). It is a fully humanized IgG1γ monoclonal antibody directed against soluble B lymphocyte stimulator (BLyS). It is indicated as an add-on therapy for the treatment of adult patients with active, autoantibody-positive SLE, who are receiving standard therapy. Belimumab is generally well-tolerated, common adverse effects include infections, infusion reactions, hypersensitivity, headache, nausea, and fatigue. Psychiatric events including suicidal tendency, progressive multifocal leukoencephalopathy and malignancies too have been reported. Apart from SLE, the drug is also being tried for other autoimmune disorders.
Department of Skin and VD, RUHS College of Medical Sciences and Government RDBP Jaipuria Hospital, Jaipur, Rajasthan, India.
Ankita
A
Srivastava
Adverse effects; B lymphocyte stimulator; belimumab; systemic lupus erythematosus
J Rheumatol. 2014 Feb;41(2):300-9
24187095
Lancet. 2011 Feb 26;377(9767):721-31
21296403
Cell Biochem Biophys. 2009;53(1):1-16
19034695
Nat Biotechnol. 2012 Jan 09;30(1):69-77
22231104
RMD Open. 2015 Mar 03;1(1):e000011
26509047
Lupus. 2014 Jun;23(7):711-3
24531080
Lupus. 2013 Feb;22(2):144-54
23213069
J Pharmacol Pharmacother. 2015 Apr-Jun;6(2):71-6
25969652
Biomed Res Int. 2014;2014:704207
25243173
Arthritis Rheum. 2011 Dec;63(12):3918-30
22127708
Drug Des Devel Ther. 2015 Jan 07;9:333-47
25609919
J Pharmacol Pharmacother. 2011 Oct;2(4):317-9
22025872
Ther Adv Musculoskelet Dis. 2015 Aug;7(4):115-21
26288663
Indian J Dermatol. 2009;54(2):100-9
20101303
Arthritis Rheum. 2012 Oct;64(10):3364-73
22674457